Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
AssigneeAnGes MG, Inc.
InventorKensuke Egashira
Life of this patent
Estimating the term…
Abstract
Compositions and methods for inhibiting inflammation of vessel wall and/or formation of neointimal hyperplasia by gene therapy using a soluble Flt-1 (sFlt-1) gene, are provided. VEGF has an essential role in the development of neointimal hyperplasia by causing inflammation. sFlt-1 gene transfer to the site of vascular injury blocks Flt-1-mediated VEGF signal transduction, thereby inhibiting early inflammation as well as late neointimal hyperplasia. The present invention is useful for inhibiting or treating inflammation of vessel wall and/or formation of neointimal hyperplasia in a patient with risk of post coronary intervention restenosis, atherosclerosis, arteriosclerosis, or edema.
Claims30
A composition comprising a nucleic acid encoding soluble Flt-1 (sFlt-1) and a pharmaceutically acceptable carrier, wherein said nucleic acid expresses sFlt-1 in an amount effective to inhibit or treat inflammation of vessel wall and/or formation of neointimal hyperplasia.
Use of a nucleic acid encoding soluble Flt-1 (sFlt-1) for the production of a pharmaceutical composition for inhibiting or treating inflammation of vessel wall and/or formation of neointimal hyperplasia.
A method for inhibiting or treating inflammation of vessel wall and/or formation of neointimal hyperplasia, comprising administration of a nucleic acid encoding soluble Flt-1 (sFlt-1) to a patient in need thereof.
Dependencies are inferred from the claim text.